Navigation Links
Drug Cures Osteoporosis in Mice
Date:2/8/2010

Experimental agent targets serotonin in the gut, triggering bone formation

MONDAY, Feb. 8 (HealthDay News) -- An experimental drug that inhibits serotonin in the gut cured osteoporosis in lab mice and rats, a new study has found.

Previous research has shown that serotonin in the gut hinders bone formation. Most current drugs for osteoporosis only prevent the breakdown of bone; they don't build bone.

"New therapies that inhibit the production of serotonin in the gut have the potential to become a [new] class of drugs to be added to the therapeutic arsenal against osteoporosis," study author Dr. Gerard Karsenty, chairman of the department of genetics and development at Columbia University College of Physicians and Surgeons, said in a university news release.

In the new study, published in the Feb. 7 issue of Nature Medicine, small daily doses of the new drug were given by mouth for up to six weeks to rodents with postmenopausal osteoporosis. The treatment prevented osteoporosis from developing or fully cured rodents in which osteoporosis was already present.

While the drug inhibited serotonin in the gut, levels of serotonin remained normal in the rodents' brains. This indicates that the drug didn't enter general circulation and wasn't able to cross the blood-brain barrier, thus greatly reducing the risk of side effects.

"With tens of millions of people worldwide affected by this devastating and debilitating bone loss, there is an urgent need for new treatments that not only stop bone loss but also build new bone. Using these findings, we are working hard to develop this type of treatment for human patients," Karsenty said.

More information

The American College of Rheumatology has more about osteoporosis.



-- Robert Preidt



SOURCE: Columbia University, news release, Feb. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Constipations Many Causes and Cures
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
4. Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn
5. UI licensee Optherion secures $37 million in financing
6. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
7. Piedmont Pharmaceuticals Secures $8.5 Million Investment
8. St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chilis Care Center
9. The blood-brain barrier: A misunderstood key to finding life-saving cures to brain disease
10. Study paves way for development of macular degeneration cures
11. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...   Genomic Health, Inc. (Nasdaq: GHDX ) today ... ended December 31, 2015. --> --> ... compared with $69.1 million in the fourth quarter of 2014, an ... 9 percent compared with the same period in the prior year. ... $63.9 million in the fourth quarter of 2015, an increase of ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
Breaking Medicine Technology: